Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Charles River Laboratories International

Request full access

Research models, and outsourced preclinical services for the accelerated r&d of drugs

Wilmington, United StatesFounded 1947Biotech & Life Sciences

About Charles River Laboratories International

Charles River Laboratories, accessible via criver.com, is a pioneering company in the life sciences sector, dedicated to advancing the discovery, development, and safe manufacture of novel drugs and therapies. With a legacy of 70 years, Charles River has been at the forefront of innovation, particularly in the responsible advancement of alternative methods in animal research, focusing on replacement, reduction, and refinement.

The company operates in the biopharmaceutical market, serving a diverse clientele that includes pharmaceutical and biotechnology companies, government agencies, and academic institutions. Charles River offers a broad range of services, from basic research to comprehensive solutions for antibody discovery and cell therapy manufacturing. Their services are designed to accelerate the development of biopharmaceuticals from concept to cure, ensuring compliance with current Good Manufacturing Practices (CGMP).

Charles River's business model revolves around providing flexible and scalable testing platforms and manufacturing services. These platforms can be deployed at client facilities, satellite labs, or within Charles River's own extensive network of over 100 facilities in more than 20 countries. This flexibility allows clients to expedite their research and development processes efficiently.

Revenue generation for Charles River comes from offering specialized contract research and manufacturing services. These services include biologics contract manufacturing, antibody discovery, and cell therapy manufacturing, all tailored to meet the unique needs of their clients. Additionally, the company invests heavily in environmental, social, and governance (ESG) strategies, aiming to achieve 100% renewable electricity globally by 2030, which underscores their commitment to sustainability.

In summary, Charles River Laboratories is a key player in the life sciences industry, providing essential services that support the development of new drugs and therapies, with a strong emphasis on innovation, flexibility, and sustainability.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2000
Employees
10,608
Open positions
172
Dealroom signal
27.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology, Health Platform
Sector
Biotechnology, Drug Development, Horizon Europe
Business model
Manufacturing
Client focus
B2B
Investment activity
39 companies, latest Jan 2026
Capital deployed
$303M
Preferred round
ACQUISITION

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO DEBT✓Debt Dec 2024 $0 — Undisclosed ↗
GRANTOther financing Jun 2024 $1.3M — Undisclosed ↗
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Charles River Laboratories International website traffic

Latest recorded traffic for Charles River Laboratories International is 230K monthly website visits, up 27.8% over the last three months. Charles River Laboratories International's team grew 0% over the past year.

Latest monthly visits230K 3-month web change+27.8% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Charles River Laboratories International in the Wilmington ecosystem

Live from Dealroom

The Charles River Laboratories International office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • National Institutes of Health

Series B and later1 investor entered at this stage

  • Tinicum

Other known investors4 additional known investors

  • Avista Healthcare Partners
  • European Equity Partners
  • EW Healthcare Partners
  • New Leaf Venture Partners
Team profiled 36 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Wilmington HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Charles River Laboratories International on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Charles River Laboratories International’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.